New drug PALI-2108 studied for Crohn's scarring
NCT ID NCT07428096
First seen Mar 02, 2026 · Last updated Apr 25, 2026 · Updated 7 times
Summary
This study tests an experimental drug called PALI-2108 in 6 adults with fibrostenotic Crohn's disease, a condition where the gut becomes scarred and narrow. Participants take the drug for 14 days, and researchers analyze tissue samples to see how it affects inflammation and scarring at the molecular level. The goal is to learn how the drug works, not to prove it treats the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSTENOTIC CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences
Montreal, Quebec, H3P3H5, Canada
Conditions
Explore the condition pages connected to this study.